<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Surgical management of hereditary diffuse gastric cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Surgical management of hereditary diffuse gastric cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Surgical management of hereditary diffuse gastric cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Pamela Hebbard, MD, FRCS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David I Soybel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse gastric carcinoma (DGC) is a highly invasive tumor that is characterized by a late presentation and poor prognosis [
         <a href="#rid1">
          1
         </a>
         ]. An inherited form of DGC, hereditary diffuse gastric cancer (HDGC), can be caused by pathogenic variants in the cadherin-1 (
         <em>
          CDH1
         </em>
         ) gene [
         <a href="#rid2">
          2-4
         </a>
         ] or the alpha catenin (
         <em>
          CTNNA1
         </em>
         ) gene [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The lifetime risk of developing gastric cancer for carriers of a
         <em>
          CDH1
         </em>
         pathogenic variant from HDGC families is high. By the 2010 HDGC clinical criteria, 70 percent of males and 56 percent of females will develop gastric cancer by age 80 [
         <a href="#rid6">
          6
         </a>
         ]; by the less stringent 2015 HDGC clinical criteria, 42 percent of males and 33 percent of females will develop gastric cancer by age 80 [
         <a href="#rid7">
          7,8
         </a>
         ]. As such, prophylactic total gastrectomy is often recommended at an early age [
         <a href="#rid9">
          9-14
         </a>
         ].
        </p>
        <p>
         The surgical management of HDGC will be reviewed here. The genetics and pathogenesis of HDGC, as well as issues related to screening for HDGC and surveillance for breast and other cancers in
         <em>
          CDH1
         </em>
         mutation carriers, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119517.html" rel="external">
          "Gastric cancer: Pathology and molecular pathogenesis", section on 'Hereditary diffuse gastric cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H356068545">
         <span class="h1">
          INDICATIONS FOR PROPHYLACTIC TOTAL GASTRECTOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management strategy for suspected or confirmed hereditary diffuse gastric cancer (HDGC) is outlined briefly below but discussed in detail elsewhere  (
         <a class="graphic graphic_algorithm graphicRef131798" href="/z/d/graphic/131798.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Management of CDH1 variant carriers'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CDH1
         </em>
         pathogenic variant carrier from HDGC family – Prophylactic total gastrectomy is the recommended approach [
         <a href="#rid15">
          15-17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Diffuse gastric cancer in the family'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CDH1
         </em>
         pathogenic variant carrier not from HDGC family – With the inclusion of
         <em>
          CDH1
         </em>
         on many multigene cancer panels [
         <a href="#rid18">
          18-20
         </a>
         ], individuals may be identified as having a
         <em>
          CDH1
         </em>
         pathogenic variant but may not have a personal or family history of diffuse gastric cancer [
         <a href="#rid21">
          21
         </a>
         ]. For such individuals, endoscopic surveillance rather than upfront prophylactic total gastrectomy is generally the preferred approach, but patients may seek individualized evaluation at an experienced center for consideration of prophylactic total gastrectomy [
         <a href="#rid16">
          16-18,20-22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'No family history of diffuse gastric cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CDH1
         </em>
         variant of unknown significance carrier – Endoscopic surveillance rather than upfront prophylactic total gastrectomy is generally the preferred approach [
         <a href="#rid16">
          16,23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Variants of uncertain significance or HDGC-like families'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDGC-like family member and first-degree relative – HDGC-like families are defined as fulfilling HDGC genetic testing criteria but having no identified
         <em>
          CDH1
         </em>
         or
         <em>
          CTNNA1
         </em>
         pathogenic variant. Such families must have at least one confirmed case of diffuse gastric cancer and another gastric cancer or lobular breast cancer in first-degree or second-degree relatives. Endoscopic surveillance rather than upfront prophylactic total gastrectomy is generally the preferred approach [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          CTNNA1
         </em>
         pathogenic variant carrier – The role of gastrectomy for carriers of the
         <em>
          CTNNA1
         </em>
         pathogenic variant is less well established, and the decision about prophylactic total gastrectomy versus endoscopic surveillance is individualized and is influenced by the penetrance of diffuse gastric cancer in the family. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Carriers of CTNNA1 pathogenic or likely pathogenic variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          TIMING OF PROPHYLACTIC TOTAL GASTRECTOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic gastrectomy is often advised as early as age 20. However, patients recommended for prophylactic gastrectomy may refuse or wish to postpone surgery. For patients who wish to delay prophylactic total gastrectomy, age, fertility considerations, family phenotypes (especially the age of onset of clinical cancer in probands), and preexisting nutritional disorders should also be taken into account. The estimated risk of neoplastic disease and the anticipated reduction in risk that is achieved through surgical intervention should be weighed against the negative outcomes of surgery, including complications associated with total gastrectomy and gastrointestinal reconstruction. (See
         <a class="medical medical_review" href="/z/d/html/89634.html" rel="external">
          "Postgastrectomy complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H356070220">
         <span class="h2">
          Age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient age, especially at both extremes, should be a consideration in any discussion of prophylactic total gastrectomy. As with other inherited cancer susceptibility syndromes, the age at which a prophylactic procedure is recommended should be based upon the presence of a known pathogenic mutation and the age of onset of disease in the pedigree [
         <a href="#rid25">
          25
         </a>
         ]. The potential physical and psychological ramifications of a total gastrectomy should be balanced with the penetrance pattern of a particular kindred.
        </p>
        <p class="headingAnchor" id="H356071181">
         <span class="h3">
          Young patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic gastrectomy is often advised as early as age 20 [
         <a href="#rid16">
          16,26
         </a>
         ]. Although the mean age of onset of diffuse gastric cancer documented in the literature is approximately 38, there are certain kindreds in which the mean age of onset is much younger [
         <a href="#rid27">
          27
         </a>
         ]. Early prophylactic total gastrectomy may be justified in such kindreds due to the observation that disease tends to develop at a younger age in successive generations of affected individuals, a phenomenon referred to as genetic anticipation. Some suggest timing total gastrectomy in
         <em>
          CDH1
         </em>
         mutation carriers at an age that is five years younger than that of the youngest family member who developed gastric cancer [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H356071187">
         <span class="h3">
          Older patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older patients are less likely to benefit from a prophylactic gastrectomy than younger patients because of a shorter life expectancy and a higher perioperative risk.
        </p>
        <p>
         Although the upper age limit for performing prophylactic gastrectomy is not well defined, some guidelines recommend that patients who are older than 70 years should not undergo such a procedure, as their mortality from the procedure may outweigh their mortality from gastric cancer [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Decisions about prophylactic gastrectomy in middle-aged and older patients who are younger than 70 years should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred. If the onset of disease in the family is early, older patients may live out their natural life expectancy without ever developing gastric cancer.
        </p>
        <p class="headingAnchor" id="H433650">
         <span class="h2">
          Eating disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         As patients can be expected to lose 10 to 15 percent of their body weight following total gastrectomy, those with eating disorders such as bulimia and anorexia nervosa are at high risk of developing physical and/or psychological complications after surgery [
         <a href="#rid30">
          30,31
         </a>
         ]. Thus, the potential risk of gastric cancer must be weighed against the severity of eating disorders before a prophylactic gastrectomy is carried out.
        </p>
        <p>
         We do not perform total gastrectomy in patients who are malnourished, actively losing weight, or who have a body mass index less than 18 to 20 kg/m
         <sup>
          2
         </sup>
         . In addition, for any patient with a known or suspected eating disorder, we pursue psychiatric assessment and close collaboration with an established multidisciplinary eating disorder treatment team to give the patient the best chance of achieving long-term healthy weight control. (See
         <a class="local">
          'Nutritional evaluation and counseling'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H356070338">
         <span class="h2">
          Women of childbearing age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total gastrectomy is known to cause weight loss, and low body weight is a known risk factor for female infertility (see
         <a class="medical medical_review" href="/z/d/html/5448.html" rel="external">
          "Female infertility: Treatments", section on 'Low body weight'
         </a>
         ). Nevertheless, gastric surgery does not preclude future pregnancy. At least three pregnancies following prophylactic total gastrectomy have been described [
         <a href="#rid32">
          32
         </a>
         ]. All three delivered normal infants at term. In addition, over 150 pregnancies after gastrectomy for various other indications have also been reported [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p>
         Thus, for those of childbearing age, the risk of infertility must be balanced against the risk of developing a likely fatal cancer. Given that this cancer can strike in childbearing years and has high fatality, people are waiting longer before birthing their first child, and that there is no good evidence that the surgery impacts fertility, we do
         <strong>
          not
         </strong>
         advise delaying prophylactic total gastrectomy (eg, until having all desired children or after having at least one child).
        </p>
        <p>
         For those who become pregnant after gastric surgery, appropriate monitoring and supplementation for nutritional deficiencies is required to avoid maternal anemia and fetal malformation (eg, neural tube defects from folate deficiency). An interval of 6 to 12 months is recommended between prophylactic total gastrectomy and future pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/411.html" rel="external">
          "Fertility and pregnancy after bariatric surgery", section on 'Micronutrient supplementation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H356069452">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients contemplating prophylactic total gastrectomy should be evaluated and managed by a multidisciplinary team that includes primary care providers, medical specialists, surgeons, geneticists, nutritionists, and psychologists.
        </p>
        <p class="headingAnchor" id="H110033315">
         <span class="h2">
          Genetic and family counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary diffuse gastric cancer (HDGC) is inherited in an autosomal dominant fashion, with most cases resulting from germline pathogenic variants in the
         <em>
          CDH1
         </em>
         gene [
         <a href="#rid2">
          2-4
         </a>
         ]. HDGC should be suspected in any case of diffuse gastric cancer diagnosed in a patient under the age of 50 years and prompt genetic testing of the patient and family members [
         <a href="#rid13">
          13,16
         </a>
         ]. Specific criteria for genetic testing for
         <em>
          CDH1
         </em>
         pathogenic variants in patients with suspected HDGC are addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Genetic counseling and testing'
         </a>
         .)
        </p>
        <p>
         Female members of the kindred should be made aware that the risk for lobular breast cancer is also increased. Females with
         <em>
          CDH1
         </em>
         germline pathogenic or likely pathogenic variants have a 43 to 55 percent risk of developing lobular breast cancer by age 80 [
         <a href="#rid7">
          7,8
         </a>
         ]. Most guidelines suggest that mutation carriers be managed as are other females with high-risk inherited conditions such as
         <em>
          BRCA
         </em>
         mutations [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/758.html" rel="external">
          "Cancer risks and management of BRCA1/2 carriers without cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H356069524">
         <span class="h2">
          Nutritional evaluation and counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional counseling should be provided by an experienced dietician to educate the patient about potential long-term nutritional deficiencies after total gastrectomy [
         <a href="#rid35">
          35
         </a>
         ]. Micronutrients most commonly depleted after total gastrectomy include several water-soluble vitamins (eg,
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         ), fat-soluble vitamins (eg, vitamins A, D, E, and K), and trace minerals, including iron and calcium. A detailed discussion of postgastrectomy nutrient deficiencies is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/587.html" rel="external">
          "Bariatric surgery: Postoperative nutritional management", section on 'Micronutrient management'
         </a>
         .)
        </p>
        <p>
         The patient should also be educated about other postgastrectomy complications, which are expected to occur to a greater or lesser extent in almost everyone who undergoes total gastrectomy [
         <a href="#rid36">
          36
         </a>
         ]. Dietary and medical therapies are usually effective in dealing with most postgastrectomy syndromes. Surgical reintervention is rarely needed. (See
         <a class="medical medical_review" href="/z/d/html/89634.html" rel="external">
          "Postgastrectomy complications"
         </a>
         .)
        </p>
        <p>
         It is important for the patient to be aware that recovery from prophylactic total gastrectomy and return to a new "normal" eating pattern may take up to one year, during which time they are expected to lose 10 to 20 percent of their body weight [
         <a href="#rid17">
          17
         </a>
         ]. It is advisable that patients speak with others who have undergone this operation and who will be able to act as a source of support during recovery from the operation.
        </p>
        <p class="headingAnchor" id="H110033098">
         <span class="h2">
          Preoperative imaging and endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative preparation for prophylactic total gastrectomy includes abdominal imaging, upper endoscopy, and colonoscopy to ensure there is not an undiagnosed malignancy, as this would markedly change the operative approach. (See
         <a class="local">
          'Patients who have known invasive gastric cancer'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H110033124">
         <span class="h3">
          Abdominal imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient being evaluated for prophylactic gastrectomy should undergo computed tomography (CT) evaluation of the abdomen preoperatively to rule out the presence of a mass or any other signs of malignancy, such as lymphadenopathy, peritoneal carcinomatosis, or liver metastasis [
         <a href="#rid13">
          13
         </a>
         ]. Positron emission tomography (PET) scanning can be performed for further staging, but only if gastric cancer is suspected by CT imaging or endoscopy.
        </p>
        <p class="headingAnchor" id="H110033130">
         <span class="h3">
          Endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative evaluation prior to prophylactic gastrectomy should include upper endoscopy with at least 30 biopsies taken randomly from the antrum, incisura, fundus, and body of the stomach as well as any grossly abnormal (eg, pale) areas [
         <a href="#rid16">
          16,37
         </a>
         ].
        </p>
        <p>
         For all patients in whom total gastrectomy is anticipated, the gastroesophageal junction should be carefully examined by upper endoscopy, and the presence of Barrett esophagus or hiatal herniation should also be noted. A shortened esophagus will alter the surgical approach and may require extension of the incision into the thorax. If magnifying endoscopy methodology (eg, narrow band imaging, chromoendoscopy) is available, it can be used as a part of the endoscopic evaluation [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2650.html" rel="external">
          "Barrett's esophagus: Evaluation with optical chromoscopy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2670.html" rel="external">
          "Chromoendoscopy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          GASTRECTOMY AND RECONSTRUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic total gastrectomy should be performed by a surgeon who is familiar with hereditary diffuse gastric cancer (HDGC) and performs the procedure on a regular basis.
        </p>
        <p class="headingAnchor" id="H433422">
         <span class="h2">
          Margins of resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the
         <em>
          CDH1
         </em>
         pathogenic variant is present in all gastric tissues, the surgeon must be sure to remove the entire stomach during prophylactic gastrectomy. The distal margin of resection should be carried to duodenal mucosa least 1 cm beyond the pylorus [
         <a href="#rid6">
          6
         </a>
         ]. Before gastrointestinal reconstruction, frozen section should be obtained of the proximal margin to confirm squamous esophageal mucosa and a lack of residual gastric mucosa, which increases the risk for future malignancy.
        </p>
        <p>
         In a review of 29 prophylactic gastrectomies, three patients required reintervention due to incomplete removal of proximal gastric mucosa [
         <a href="#rid39">
          39
         </a>
         ]. In another study of 44 cases, intraoperative frozen section of the proximal margin identified residual gastric mucosa in two patients and occult malignancy in one [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H356072238">
         <span class="h2">
          Minimally invasive versus open gastrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic total gastrectomy in otherwise asymptomatic patients may be an ideal situation for the minimally invasive approach since perigastric lymph node harvest is not necessarily needed in the absence of invasive disease [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="local">
          'Extent of lymph node dissection'
         </a>
         below.)
        </p>
        <p>
         At experienced centers, minimally invasive prophylactic total gastrectomy has been used to treat asymptomatic carriers of a
         <em>
          CDH1
         </em>
         pathogenic variant with a family history of HDGC in up to 40 percent of cases [
         <a href="#rid17">
          17,41
         </a>
         ]. Compared with open surgery, minimally invasive prophylactic total gastrectomy was associated with longer operative time but shorter hospital stay and greater lymph node recovery [
         <a href="#rid17">
          17
         </a>
         ]. Nevertheless, minimally invasive surgery impacts mostly short-term rather than long-term outcomes. Thus, the surgical approach is not as important as the experience of the surgeon.
        </p>
        <p>
         The techniques of minimally invasive gastrectomy are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/109436.html" rel="external">
          "Laparoscopic gastrectomy for cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Extent of lymph node dissection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of a confirmed invasive malignancy, the approaches to lymph node dissection for prophylactic gastrectomy vary greatly by surgeon preference:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform a conservative harvest of perigastric nodal tissue along the greater and lesser curves of the stomach but preserve the omentum. Such a practice provides reasonable nodal sampling in case an occult malignancy is found on final pathology but does not expose the patient to unnecessary harm that may be associated with a more extensive lymph node dissection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some surgeons do not perform a formal lymph node dissection, taking only those lymph nodes that are harvested during the course of gastric resection. This approach may be reasonable because the majority of these patients will have no more than pT1a cancers  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 1
         </a>
         ), from which no lymph node metastases have been reported [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other surgeons advocate a D1 (perigastric nodes plus omentum) or D1+ (D1 plus left/right gastric artery and hepatic artery nodes) lymph node dissection with prophylactic gastrectomy just in case T1b or higher-stage disease is found on final pathology [
         <a href="#rid16">
          16
         </a>
         ]. Preoperative upper endoscopy cannot exclude pT1b lesions  (
         <a class="graphic graphic_table graphicRef111190" href="/z/d/graphic/111190.html" rel="external">
          table 1
         </a>
         ), which carry a higher risk of lymph node metastases (17 to 28 percent of cases depending on depth of submucosal invasion [
         <a href="#rid42">
          42
         </a>
         ]). (See
         <a class="medical medical_review" href="/z/d/html/2520.html" rel="external">
          "Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In any case, a D2 lymph node dissection is
         <strong>
          not
         </strong>
         performed in the absence of confirmed malignancy, due to higher associated morbidities [
         <a href="#rid16">
          16
         </a>
         ]. The approaches to therapeutic lymph node dissection (eg, D1 versus D2) for invasive gastric cancer patients are controversial and are discussed in another topic. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Extent of lymph node dissection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Reconstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following total gastrectomy for any indication, the ideal method of reconstruction preserves duodenal and jejunal continuity and provides a functional reservoir to minimize functional and nutritional disturbances [
         <a href="#rid36">
          36,43,44
         </a>
         ]. Gastrointestinal reconstruction following total gastrectomy is not standardized. The various techniques for reconstruction following total gastrectomy are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15166.html" rel="external">
          "Total gastrectomy and gastrointestinal reconstruction", section on 'Gastrointestinal reconstruction'
         </a>
         .)
        </p>
        <p>
         Following total gastrectomy for hereditary diffuse gastric cancer, we prefer to use a Roux-en-Y esophagojejunostomy with pouch reconstruction when feasible  (
         <a class="graphic graphic_figure graphicRef89207" href="/z/d/graphic/89207.html" rel="external">
          figure 1
         </a>
         ). Jejunal pouch reconstruction may provide some quality-of-life benefits in the short term [
         <a href="#rid44">
          44,45
         </a>
         ] but is not universally endorsed. A temporary feeding jejunostomy tube may be placed for postoperative nutritional support in patients who are expected to have a complicated or delayed recovery.
        </p>
        <p class="headingAnchor" id="H1244150790">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The surgical specimen of a prophylactic total gastrectomy should be analyzed following a specific institutional protocol. Both the World Health Organization (WHO) and Lauren classifications should be reported [
         <a href="#rid46">
          46,47
         </a>
         ]. Most lesions in HDGC are tiny foci of typical signet cells confined to the superficial lamina propria, rather than infiltrating the muscularis mucosae. By contrast, advanced HDGC predominantly presents as linitis plastica [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119517.html" rel="external">
          "Gastric cancer: Pathology and molecular pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylactic total gastrectomy performed for carriers of a
         <em>
          CDH1
         </em>
         pathogenic or likely pathogenic variant carries a perioperative mortality rate of 0 to 2.5 percent [
         <a href="#rid12">
          12,17,48
         </a>
         ], a perioperative morbidity of rate of about 30 percent [
         <a href="#rid17">
          17,48
         </a>
         ], and a long-term morbidity rate of about 20 percent [
         <a href="#rid17">
          17,48
         </a>
         ].
        </p>
        <p>
         For patients presenting with a clinically detected cancer, the outcome is significantly reduced. More specifically, a retrospective study of 99 pathogenic
         <em>
          CDH1
         </em>
         variant carriers within the FREGAT (FRench Eso-GAsTric tumor) network reported that the prognosis of the index patients is dismal, with a median survival of 12 (7.6 to 16.4) months because peritoneal carcinomatosis was present in 71 percent at diagnosis. Among the 77 nonindex patients who underwent prophylactic total gastrectomy, cancer was detected on specimens in 54.5 percent (n = 42, all pT1a), of which 59.5 percent had no cancer detected on preoperative endoscopy (n = 25) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Major complications after total gastrectomy include surgical site infection, anastomotic leak and sepsis, and late esophageal stricture [
         <a href="#rid30">
          30,50
         </a>
         ]. The major potential long-term morbidities associated with total gastrectomy include some degree of malabsorption, dumping syndrome, diarrhea, and a 10 to 20 percent decrease in body weight [
         <a href="#rid17">
          17,31,50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89634.html" rel="external">
          "Postgastrectomy complications"
         </a>
         .)
        </p>
        <p>
         Studies of patient-reported outcomes and attitudes in patients having undergone prophylactic gastrectomy have shown favorable physical and psychological recovery from the procedure, with the majority of patients generally feeling positive about their decision [
         <a href="#rid48">
          48,51-53
         </a>
         ]. In reported series, only 6 to 10 percent of patients report worse quality of life after the procedure or regret their decision to have surgery [
         <a href="#rid48">
          48,54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H36588505">
         <span class="h1">
          PATIENTS WHO DEFER OR REFUSE SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients at risk for hereditary diffuse gastric carcinoma (HDGC) who refuse or wish to delay prophylactic total gastrectomy, we suggest close endoscopic surveillance.
        </p>
        <p>
         The suggested endoscopic protocol, based on limited data, calls for annual white-light high-definition endoscopic examination with 28 to 30 biopsies (three to five from cardia, five from fundus, 10 from body, five from transition zone, and five from antrum) evaluating for intramucosal signet ring cell carcinoma (SRCC) [
         <a href="#rid6">
          6,16,55
         </a>
         ].
        </p>
        <p>
         However, patients must be fully educated about the shortcomings of this approach. The theoretical number of biopsies necessary to discover one focus of SRCC was estimated at 1768 (range 50 to 5832) at a 90 percent detection rate [
         <a href="#rid56">
          56
         </a>
         ]. Further, multiple mucosal biopsies have failed to identify SRCC that lies beneath an intact mucosal lining in many carriers of a
         <em>
          CDH1
         </em>
         pathogenic variant who are undergoing prophylactic total gastrectomy [
         <a href="#rid9">
          9,11-13
         </a>
         ]. We suggest periodically revisiting the option of surgery with patients who initially declined it as they may reconsider when life circumstances permit [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Endoscopic assessment'
         </a>
         .)
        </p>
        <p>
         Occasionally a patient followed endoscopically for HDGC will have a biopsy that is positive for intramucosal SRCC but lack endoscopic evidence of erosion, a disturbed vascular and pit pattern, or histopathologic signs of invasion into or beyond the muscularis mucosa (T1a). We typically advise such patients to undergo prophylactic total gastrectomy because accurate local staging is difficult with HDGC. For those who still wish to forego gastrectomy after appropriate counselling, guidelines recommend repeating endoscopic surveillance at six-month intervals [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1836494354">
         <span class="h1">
          PATIENTS WHO HAVE KNOWN INVASIVE GASTRIC CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a family history of hereditary diffuse gastric cancer who have biopsy-proven invasive gastric cancer should be staged and managed according to guidelines set for nonhereditary gastric cancer and should undergo a therapeutic (as opposed to prophylactic) total gastrectomy with appropriate levels of lymph node dissection.
        </p>
        <p>
         The indications for and techniques of gastrectomy in patients with proven gastric cancer are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2237969247">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114875.html" rel="external">
          "Society guideline links: Gastric cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/134311.html" rel="external">
          "Society guideline links: Gastric surgery for cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Hereditary diffuse gastric cancer (HDGC) is an inherited form of diffuse type gastric cancer, which results from a germline pathogenic or likely pathogenic variant of the cadherin-1 (
         <em>
          CDH1
         </em>
         ) gene or the alpha catenin (
         <em>
          CTNNA-1
         </em>
         ) gene. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of asymptomatic individuals with either a pathologic variant of the
         <em>
          CDH1
         </em>
         or
         <em>
          CTNNA-1
         </em>
         gene and/or a family history of diffuse gastric cancer is discussed  (
         <a class="graphic graphic_algorithm graphicRef131798" href="/z/d/graphic/131798.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Indications for prophylactic total gastrectomy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2511.html" rel="external">
          "Hereditary diffuse gastric cancer", section on 'Management of CDH1 variant carriers'
         </a>
         .):
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of surgery
         </strong>
         – The optimal timing of prophylactic total gastrectomy for patients at risk of developing HDGC is as early as age 20. However, a patient's age, fertility considerations, family phenotype (especially the age of onset of clinical cancer in probands), and preexisting nutritional disorders should also be taken into account when making a decision for surgery. (See
         <a class="local">
          'Timing of prophylactic total gastrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative workup
         </strong>
         – Preoperative computed tomography (CT) imaging and upper and lower endoscopy are carried out to exclude occult malignancy. Upper endoscopy is also used to assess the location of the gastroesophageal junction to determine the best surgical approach. (See
         <a class="local">
          'Preoperative imaging and endoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical techniques
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrectomy
         </strong>
         – During prophylactic total gastrectomy, the surgeon must ensure that the entire stomach is removed. The proximal (esophageal) and distal (duodenal) margin must be checked by frozen section to ensure that it is free from any residual gastric tissue. (See
         <a class="local">
          'Margins of resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lymphadenectomy
         </strong>
         – The extent of lymph node dissection required for asymptomatic patients undergoing prophylactic total gastrectomy is controversial. We perform a conservative nodal sampling of perigastric nodes but preserve the omentum. (See
         <a class="local">
          'Extent of lymph node dissection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reconstruction
         </strong>
         – Following total gastrectomy in patients undergoing prophylactic gastrectomy, gastrointestinal reconstruction is not standardized. Jejunal pouch reconstruction may provide short-term quality-of-life benefits and is our preferred method of reconstruction following prophylactic total gastrectomy for HDGC. (See
         <a class="local">
          'Reconstruction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15166.html" rel="external">
          "Total gastrectomy and gastrointestinal reconstruction", section on 'Gastrointestinal reconstruction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical outcomes
         </strong>
         – Prophylactic total gastrectomy performed for
         <em>
          CDH1
         </em>
         mutations carries a perioperative mortality rate of 0 to 2.5 percent, a perioperative morbidity rate of about 30 percent, and a long-term morbidity rate of about 20 percent. The majority of patients show physical and psychological recovery from the procedure at 12 months after surgery and feel positive about their decision to have surgery. (See
         <a class="local">
          'Outcomes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15166.html" rel="external">
          "Total gastrectomy and gastrointestinal reconstruction", section on 'Perioperative morbidity and mortality'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89634.html" rel="external">
          "Postgastrectomy complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1130523314">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Debrah Wirtzfeld, MD, MSc, FRCSC, FACS, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van der Kaaij RT, Koemans WJ, van Putten M, et al. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. Eur J Cancer 2020; 130:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998; 58:4086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majewski IJ, Kluijt I, Cats A, et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 2013; 229:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. JAMA Oncol 2019; 5:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xicola RM, Li S, Rodriguez N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet 2019; 56:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999; 36:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008; 32:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 2009; 16:1890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008; 112:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinheiro H, Oliveira C, Seruca R, Carneiro F. Hereditary diffuse gastric cancer - pathophysiology and clinical management. Best Pract Res Clin Gastroenterol 2014; 28:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamble LA, Heller T, Davis JL. Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review. JAMA Surg 2021; 156:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020; 21:e386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vos EL, Salo-Mullen EE, Tang LH, et al. Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surg 2020; 155:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014; 16:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014; 32:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012; 91:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katona BW, Clark DF, Domchek SM. CDH1 on Multigene Panel Testing: Look Before You Leap. J Natl Cancer Inst 2020; 112:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs MF, Dust H, Koeppe E, et al. Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer. Gastroenterology 2019; 157:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee K, Krempely K, Roberts ME, et al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. Hum Mutat 2018; 39:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297:2360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer 2008; 113:1850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 2006; 4:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001; 130:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liedman B, Andersson H, Bosaeus I, et al. Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial. World J Surg 1997; 21:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG. Pregnancy after prophylactic total gastrectomy. Fam Cancer 2010; 9:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PECK DA, WELCH JS, WAUGH JM, WILSON RB. PREGNANCY FOLLOWING GASTRIC RESECTION. Am J Obstet Gynecol 1964; 90:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PISANI BJ. Term gestation following total gastrectomy. J Am Geriatr Soc 1958; 6:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams JF. The clinical and metabolic consequences of total gastrectomy. 3. Notes on metabolic functions, deficiency states, changes in intestinal histology, and radiology. Scand J Gastroenterol 1968; 3:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am 1992; 72:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch HT, Silva E, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am 2008; 88:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadowaki S, Tanaka K, Toyoda H, et al. Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods. J Gastroenterol Hepatol 2009; 24:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluijt I, Siemerink EJ, Ausems MG, et al. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer 2012; 131:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Kingham K, Ford JM, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol 2011; 18:2594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, McBean E, Li X, et al. Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings. Surg Laparosc Endosc Percutan Tech 2013; 23:e124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roviello F, Rossi S, Marrelli D, et al. Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 2006; 94:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehnert T, Buhl K. Techniques of reconstruction after total gastrectomy for cancer. Br J Surg 2004; 91:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertler R, Rosenberg R, Feith M, et al. Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol 2009; 104:2838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fein M, Fuchs KH, Thalheimer A, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg 2008; 247:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand 1965; 64:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Washington MK, Goldberg RM, Chang GJ, et al. Diagnosis of digestive system tumours. Int J Cancer 2021; 148:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strong VE, Gholami S, Shah MA, et al. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg 2017; 266:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bres C, Voron T, Benhaim L, et al. Management of Pathogenic CDH1 Variant Carriers Within the FREGAT Network: A Multicentric Retrospective Study. Ann Surg 2022; 276:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg 2006; 202:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallowell N, Lawton J, Badger S, et al. The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). J Genet Couns 2017; 26:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muir J, Aronson M, Esplen MJ, et al. Prophylactic Total Gastrectomy: a Prospective Cohort Study of Long-Term Impact on Quality of Life. J Gastrointest Surg 2016; 20:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worster E, Liu X, Richardson S, et al. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg 2014; 260:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaurah P, Talhouk A, MacMillan A, et al. Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. Fam Cancer 2019; 18:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim YC, di Pietro M, O'Donovan M, et al. Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc 2014; 80:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita H, Lennerz JK, Chung DC, et al. Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol 2012; 36:1709.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8041 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32171106" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537325" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : E-cadherin germline mutations in familial gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751616" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10973239" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23208944" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Anα-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20591882" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31246251" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31296550" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11419427" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10593993" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Familial gastric cancer: overview and guidelines for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391748" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19408054" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18442100" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25439071" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hereditary diffuse gastric cancer - pathophysiology and clinical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33404644" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32758476" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hereditary diffuse gastric cancer: updated clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32997132" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24763289" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733792" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22703879" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31841163" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : CDH1 on Multigene Panel Testing: Look Before You Leap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30935944" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30311375" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545690" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25979631" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11729114" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18798546" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16527687" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hereditary diffuse gastric cancer: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11602891" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prophylactic total gastrectomy for familial gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9143575" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20063069" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pregnancy after prophylactic total gastrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14217654" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : PREGNANCY FOLLOWING GASTRIC RESECTION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13502017" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Term gestation following total gastrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5711477" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The clinical and metabolic consequences of total gastrectomy. 3. Notes on metabolic functions, deficiency states, changes in intestinal histology, and radiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1549803" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Postgastrectomy syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18672140" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hereditary diffuse gastric cancer: prophylactic surgical oncology implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19788603" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ease of early gastric cancer demarcation recognition: a comparison of four magnifying endoscopy methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22020549" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21424370" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23752020" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16917863" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15122602" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Techniques of reconstruction after total gastrectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19672251" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438112" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14320675" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32674220" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Diagnosis of digestive system tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27759617" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35856494" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of Pathogenic CDH1 Variant Carriers Within the FREGAT Network: A Multicentric Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16571431" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27837291" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27752808" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prophylactic Total Gastrectomy: a Prospective Cohort Study of Long-Term Impact on Quality of Life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24424140" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31273560" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24472763" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23073328" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
